To provide an effective targeted therapy, a number of prostate cancer-related antigens have been used, including prostate-specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase, Prostatic stem cell antigen (PSCA) and kalikrein-4 (KLK4)8–12. Here, FOLH1 is linked to prostate carcinoma.